Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 31, 2017Molecular TherapyOpen Access

FDA-Approved Oligonucleotide Therapies in 2017

View Full Paper
Ask AI
Bookmark
Share

Authors

CSCy A. SteinCity Of Hope National Medical CenterDCDaniela CastanottoCity Of Hope National Medical Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Stein et al. (2017) studied this question.

synapsesocial.com/papers/6a75cb2e55ab84c5da19c9efhttps://doi.org/10.1016/j.ymthe.2017.03.023
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT)2015 · 389 citations
  2. 2Defibrotide (Defitelio): A New Addition to the Stockpile of Food and Drug Administration-approved Oligonucleotide Drugs2016 · 28 citations
  3. 3<scp>BCSH</scp>/<scp>BSBMT</scp> guideline: diagnosis and management of veno‐occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation2013 · 297 citations
  4. 4Inhibition of receptor binding by high-affinity RNA ligands to vascular endothelial growth factor1994 · 184 citations
  5. 5Fibroblast growth factor 2 promotes microvessel formation from mouse embryonic aorta2003 · 18 citations